$QNTM Cashflow Statement | Understand Stock

$QNTM

$2.37 +$0.05 (2.16%) Close

$QNTM Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated interim statements of cash flows

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities
Net loss
Add (deduct) items not affecting cash
Depreciation and amortization
Impairment of right-of-use asset
Interest expense
Accretion expense
Share-based payments
Change in fair value of investments
Change in fair value of derivative liabilities
Loss on issuance of convertible debt
Unrealized foreign exchange (gain) loss
Unrealized gain on change in fair value of digital assets
Realized gain on sale of digital assets
(Gain) loss on settlement of debt
(Gain) on measurement of financial liability
Impairment loss
Gain on net investment in lease
Realized (gain) on sale of investments
Realized loss on sale of finance receivables

Changes in non-cash working capital balances
Finance receivables
Other receivables
Prepaid expenses and deposits
Note receivable
Cash used in continuing operating activities
Cash used in discontinued operating activities
Inventory
Deferred income
Trade and other payables
Cash used in operating activities
Cash acquired from acquisition of Lucid Psycheceuticals Inc.
Redemption of investments
Investing activities
Cash acquired from acquisition of Prismic Pharmaceuticals Inc.
Cash acquired from acquisition of Lucid Psycheceuticals Inc.
Redemption of investments
Purchase of investments
Purchase of equipment
Additions to intangible assets
Proceeds from sale of investments
Cash (used in) provided by continuing investing activities
Cash provided by discontinued investing activities
Net cash upon control of subsidiary
Purchases of digital assets
Proceeds from sale of digital assets
Cash (used in) provided by investing activities
Share repurchase

Financing activities
Share repurchase
Proceeds from issuance of shares, net
Repayment of notes payable
Proceeds from sale of finance receivables
Proceeds from convertible debentures
Proceeds from exercise of warrants
Payment of lease obligation
Cash provided by discontinued financing activities
Proceeds from share options exercised
Repayment of loans from tax rebate refund
Proceeds from loans (RH and Bitgo)
Cash (used in) provided by financing activities
Net decrease
Cash and cash equivalents, beginning of the year
Cash and cash equivalents, end of the year
Shares issued for debt

Net increase (decrease)
Cash and cash equivalents, beginning of the year
Cash and cash equivalents, end of the year
Non-cash transactions
Shares issued for debt (in Shares)
Exercise of warrants

Comments